Does the clinical implementation of ACC/AHA guideline reduce the risk of cardiovascular diseases through lowering diabetes mellitus occurrence

Introduction: Clinical guidelines of lifestyle modification and risk factors can reduce cardiovascular diseases (CVDs) among diabetes mellitus (DM) patients. A clinical trial was designed to assess the ACC-AHA guideline effect on CVDs primary prevention by reducing the DM incidence. Methods:A quasi-experimental study was conducted among 322 initially healthy individuals aged above 20-year-old. Fasting blood glucose (FBS) was measured at baseline and after 6, 10, and 24 months of follow up. The difference in measurement results in the different follow up periods was statistically analyzed. Results: Baseline FBS in females and males was 105.25±27.32 and 103.64±30.16 mg/dl, respectively. After sixmonth-implementing the targeted interventions, FBSs were in females and males significantly reduced by 96.08 and 96.49 mg/dl, respectively. FBS levels continued to reduce by 92.24 mg/dl in women and 90.34 mg/dl (p<0.001) in men after ten month-intervention. A reduction in FBS in female (90.18 mg/dl) and male (87.12 mg/dl) participants was verified after 24 months of active follow up (p<0.001). Conclusions: As thecorrect implementation of ACC-AHA clinical guideline led to a significant decrease in FBS, CVDs as a developing risk can be primarily prevented with the lifestyle-modifying approach for DM control.

Keywords:

Coronary artery disease , Diabetes , Lifestyle intervention , Primary prevention , Risk assessment